FinancialBuzz.com: Developments in the Biotechnology Market

NEW YORK, February 14, 2017 /PRNewswire/ --

According to a report by Grand View Research, Inc. the global biotechnology market size is expected to reach USD 604.40 billion by 2020. This is due to increasing demand for sophisticated biotech based diagnostic and therapeutic solutions. For example, recombinant technology, red biotechnology, DNA sequencing and many more are expected to serve as a high impact rendering driver during the forecasted period. An emphasis is put on the importance of the presence of government funded institutions such as the NBTB (National Biotechnology Board) and DBT (Department of Biotechnology) which are carrying out R&D and product development exercises pertaining to this field. Funding and scientific updates rendered by these institutions are likely to boost market growth over the forecast period. Mount Tam Biotechnologies, Inc. (OTC: MNTM), Elite Pharmaceuticals Inc. (OTC: ELTP), CytoDyn Inc. (OTC: CYDY), Arch Therapeutics Inc. (OTC: ARTH), Pharmacyte Biotech Inc. (OTC: PMCB)

The research indicates that the "Bioservices market is expected to witness the fastest growth over forecast period owing to, the rising clinical research activities undertaken by various pharmaceutical and biotechnological organizations. In addition, the rising demand for cost cutting, implementation of stringent government regulations and increasing complexity of biotechnological processes are some key drivers of this segment."

Mount Tam Biotechnologies, Inc. (OTC: MNTM) was established to develop, optimize and bring to market novel pharmaceutical products to improve the health and well-being of patients suffering from a range of serious disease states where there is significant unmet need. Mount Tam is focused on the discovery and development of novel mTOR inhibitors, with specific emphasis to increase levels of mTORC1 inhibition relative to levels of mTORC2 inhibition.

Yesterday, Mount Tam Biotechnologies announced, "that it will advance a novel 'rapalog', TAM-03, for further development efforts with the ultimate goal of moving TAM-03 into the clinic to treat certain advanced cancers for which current therapies are inadequate. TAM-03 delivers a differentiated mTORC1:2 profile, one that is desirable for treating certain cancers.

"We are excited to bring this compound forward and to begin testing it against a range of cancer types in both in-vitro and in-vivo pre-clinical studies. Unmet need remains high across a range of cancer types, and a compound like TAM-03 has significant potential to help patients," says Tim Powers, PhD, Chief Scientific Officer of Mount Tam Biotechnologies.

"Rapalogs have been proven effective in treating a range of cancers including advanced renal cell carcinoma, progressive neuroendocrine tumors of pancreatic origin and select breast cancers, amongst others. By aiming to improve upon this well understood approach to cancer therapy, we hope to bring a promising therapeutic option into the clinic for these patients," says Mount Tam CEO Richard Marshak.

Elite Pharmaceuticals Inc. (OTCQB: ELTP) is a specialty pharmaceutical company that is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry. Elite currently has eight commercial products being sold, additional approved products pending manufacturing site transfer and the NDA for SequestOx™, for which it received the CRL from the FDA. Its leading pipeline products include abuse-deterrent opioids which utilize the Company's patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain.

Biotechnology company, CytoDyn Inc. (OTCQB: CYDY) is focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in man and is currently in Phase 3. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.

Developer of novel liquid, gel and solid hemostatic and wound care devices, Arch Therapeutics Inc. (OTCQB: ARTH) announced that its U.S. Patent and Trademark Office has issued a broad method-of-use patent for products that contain self-assembling peptidomimetics. The patent is assigned to the Massachusetts Institute of Technology and Versitech Limited and is licensed exclusively to Arch. Arch is developing products that contain self-assembling materials, such as the AC5™ family of devices, that may provide faster, safer and improved solutions for surgical, wound and interventional care. Arch anticipates that this patent will provide further value and opportunities for its pipeline.

Clinical stage biotechnology company, Pharmacyte Biotech Inc. (OTCQB: PMCB) focuses on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, discussed the comparator arm for its upcoming clinical trial and provided additional clarification on its recent pre-IND meeting with the U.S. Food and Drug Administration regarding its upcoming clinical trial in locally advanced, inoperable pancreatic cancer. "After our pre-IND meeting I am more confident and enthusiastic than ever about PharmaCyte's ability to validate its therapy for locally advanced, inoperable pancreatic cancer in a human clinical trial," said Kenneth L Waggoner, CEO of PharmaCyte.

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only regurgitates financial or corporate news through our unique financial newswire and media platform. FinancialBuzz.com has been compensated a total of six thousand dollars for financial news dissemination and pr services by a third party non affiliate for mount tam biotechnologies, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use.

Please visit: http://www.financialbuzz.com

For further information:
Media Contact:
info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com